In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

[EX Q]: SECTION 1. KOREA VISA WAIVER PILOT PROGRAM.

(a) Congressional Findings.--The Congress finds that--
(1) travel and tourism play a major role in reducing the
United States unfavorable balance of trade;
(2) the characteristics of the Korean travel market do not
permit long-term planning for longer trips;
(3) applications for United States visas cannot now be
processed in a reasonable period of time;
(4) the Secretary of State has attempted to solve the
problem by adding additional staff to the consular section at
the United States Embassy in Seoul;
(5) unfortunately, these additions have not resulted in any
discernable improvement in reducing visa processing delays;
(6) further, it is unlikely, given the current fiscal
environment, to expect funding to be available for further
staff additions in sufficient numbers to effect any significant
improvement in the time required to process visa applications;
(7) most of the nations of the South Pacific, Europe, and
Canada do not currently require Koreans entering their
countries to have a visa, thus providing them with a serious
competitive advantage in the tourism industry;
(8) the United States territory of Guam has been permitted
by the United States Government to eliminate visa requirements
for Koreans visiting Guam, with resultant impressive increases
in travel and tourism from citizens of the Republic of Korea;
(9) any application under existing procedures to add the
Republic of Korea, or any other nation to the group of favored
nations exempted from United States visa regulations, would
require many years during which time the United States could
well lose its competitive advantages in attracting travel and
tourism from the Republic of Korea;
(10) the Republic of Korea, as a gesture of goodwill, has
already unilaterally exempted United States tourists who seek
to enter the Republic of Korea from the requirement of
obtaining a visa; and
(11) growth in Korean travel to the United States has not
kept pace with growth in travel to non-United States
destinations, and cumbersome and time-consuming visa processing
procedures are widely recognized as the cause of this loss of
market share and competitiveness with alternative destinations.
(b) Pilot Program.--The Secretary of State and the Attorney General
jointly shall establish a pilot project (in this section referred to as
the ''pilot program'') within six months of the date of the enactment
of this Act under which the requirement of paragraph (7)(B)(i)(II) of
section 212(a) of the Immigration and Nationality Act (8 U.S.C.
1182(a)(7)(B)(i)(II)) is waived during the pilot program period in the
case of any alien who meets the following requirements:
(1) National of pilot program country.--The alien is a
national of, and presents a passport issued by, the Republic of
Korea. The Republic of Korea is urged to provide machine
readable passports to its citizens in the near future.
(2) Seeking entry as tourist.--The alien is applying for
admission to the United States during the pilot program period
as a nonimmigrant visitor for pleasure (as described in section
101(a)(15)(B) of the Immigration and Nationality Act (8 U.S.C.
1101(a)(15)(B))), as part of a group tour to the United States.
(3) Period of stay.--The alien seeks to stay in the United
States for a period of not more than 15 days.
(4) Executes immigration forms.--The alien before the time
of such admission completes such immigration form as the
Attorney General shall establish.
(5) Entry into the united states.--If arriving by sea or
air, the alien arrives at the port of entry into the United
States on a carrier which has entered into an agreement with the
Immigration and Naturalization Service to guarantee transport of the
alien out of the United States if the alien is found inadmissible or
deportable by an immigration officer.
(6) Not a safety threat.--The alien has been determined not
to represent a threat to the welfare, health, safety, or
security of the United States.
(7) No previous violation.--If the alien previously was
admitted without a visa under this section, the alien must not
have failed to comply with the conditions of any previous
admission as such a nonimmigrant.
(8) Round-trip ticket.--The alien is in possession of a
round-trip transportation ticket (unless this requirement is
waived by the Attorney General under regulations).
(c) Waiver of Rights.--An alien may not be provided a waiver under
the pilot program unless the alien has waived any right--
(1) to review or appeal under this Act of an immigration
officer's determination as to the admissibility of the alien at
the port of entry into the United States, or
(2) to contest, other than on the basis of an application
for asylum, any action for deportation against the alien.
(d) Termination of Authority.--Notwithstanding any other provision
of this section, the Attorney General and the Secretary of State,
acting jointly, may terminate the pilot program under this section on
or after a date which is one year after the date of the establishment
of the pilot program if--
(1) during the preceding fiscal year, the overstay rate for
nationals of the Republic of Korea entering the United States
under the pilot program exceeds the overstay rate of such
nationals entering the United States with valid visas; and
(2) the Attorney General and the Secretary of State have
jointly determined that the pilot program is leading to a
significant increase in the number of overstays by such
nationals.
(e) Special Bond and Notification Requirements for Tour
Operators.--
(1) In general.--Nationals of the Republic of Korea may not
enter the United States under the terms of this section unless
they are accompanied for the duration of their authorized
admission period by a tour operator who has fulfilled the
following requirements:
(A) The tour operator has posted a bond of $200,000
with the Secretary of State.
(B) The Secretary of State, under such regulations
as the Secretary may prescribe, has approved an
application by the tour operator to escort tour groups
to the United States.
(C) The tour operator provides the name, address,
birthdate, passport number, and citizenship of all
prospective tour group members to the Secretary of
State no less than one business day prior to the
departure date of the group, under such regulations as
he may prescribe, in order to determine that the
prospective travelers do not represent a threat to the
welfare, health, safety, and security of the United
States.
(D) The tour operator excludes from the tour group
any person whom the Secretary of State denies
permission to travel to the United States.
(E) The tour operator provides written
certification or other such evidence prescribed by the
Secretary of State and Attorney General which documents
the return to Korea of each tour group member.
(2) Forfeiture of bonds.--Bonds posted in accordance with
this subsection shall be forfeited in whole or in part and a
tour operator's authorization to escort tours to the United
States may be suspended or revoked if the Secretary of State
finds that the tour operator--
(A) has failed to disclose a material fact in
connection with the application required under
paragraph (1)(B);
(B) fails to comply with the advance notification
and refusal requirements of paragraphs (1)(C) and
(1)(D);
(C) has failed to take adequate steps to ensure
that visitors who are being escorted to the United
States under the terms of an approved application
return to their country of residence; or
(D) is found at any time to have committed a felony
or any offense under the immigration laws of the United
States.
(f) Participation by Tour Agents.--The Secretary of State shall
periodically review the overstay rate of nationals of the Republic of
Korea that corresponds to each tour agent participating in the program
under this section. The Secretary may terminate the participation in
the program of any tour agent if the Secretary determines that the
corresponding overstay rate is excessive.
(g) Definitions.--For purposes of this section--
(1) Group tour.--The term ''group tour'' means travelers
who take advantage of group-purchased hotel or airfare
packages, as guided, supervised, and arranged by a tour agent
in the Republic of Korea approved or licensed by the Department
of State.
(2) Overstay rate.--The term ''overstay rate'' means,
during a specified period of time, the proportion that the
number of aliens remaining in the United States after the
expiration of their visas bears to the total number of aliens
entering the United States during that period of time.
(3) Pilot program period.--The term ''pilot program
period'' means the three-year period immediately following the
establishment of the pilot program.
[EX A]: Directs the Secretary of State and the Attorney General to jointly establish a visa waiver pilot program for Korean nationals traveling in tour groups to the United States. Specifies requirements for such waiver.

[EX Q]: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Commission on the Removal of
Mexican-Americans to Mexico Act''.

SEC. 2. FINDINGS; PURPOSE.

(a) Findings.--Congress finds the following:
(1) From 1929 through 1941, Federal, State, and local
Government authorities and certain private sector entities
throughout the United States undertook an aggressive program to
forcibly remove individuals of Mexican ancestry from the United
States.
(2) As many as 1,200,000 individuals of Mexican ancestry
who were United States citizens were forcibly removed to
Mexico.
(3) These men, women, and children were removed outside the
United States in response to public pressure to curtail the
employment of Mexican-Americans, most of whom were United
States citizens or residing legally in the United States,
during the Depression.
(4) Massive raids were conducted on Mexican-American
communities, and many of the people who were removed were never
able to return to the United States, their country of birth.
(5) These raids targeted individuals of Mexican ancestry,
even when such individuals were United States citizens or
permanent legal residents.
(6) These raids also separated such United States citizens
and permanent legal residents from their families and deprived
them of their livelihoods and constitutional rights.
(7) No official inquiry into this matter has been made.
(b) Purpose.--It is the purpose of this Act to establish a fact
finding commission to determine whether United States citizens and
permanent legal residents were forcibly removed to Mexico from 1929 to
1941 in violation of law as a result of past directives of Federal,
State and local governments and the impact of such removal on those
individuals, their families, and the Mexican-American community in the
United States, and to recommend appropriate remedies.

SEC. 3. ESTABLISHMENT OF COMMISSION.

There is established a commission to be known as the ''Commission
on the Removal of Mexican-Americans to Mexico''.

SEC. 4. DUTIES OF THE COMMISSION.

The Commission shall--
(1) review the facts and circumstances surrounding the
removal of certain United States citizens and permanent legal
residents to Mexico from 1929 to 1941, and the impact of such
actions on these individuals, their families, and the Mexican-
American community in the United States;
(2) review past directives of Federal, State, and local
governments that required the removal of these individuals to
Mexico and any other information related to these directives;
and
(3) submit to Congress a written report of its findings and
recommendations.

SEC. 5. MEMBERSHIP.

(a) Number and Appointment.--The Commission shall be composed of
seven members, who shall be appointed within 90 days after the date of
the enactment of this Act as follows:
(1) Three members appointed by the President.
(2) Two members appointed by the Speaker of the House of
Representatives, in consultation with the minority leader of
the House of Representatives.
(3) Two members appointed by the President pro tempore of
the Senate, in consultation with the minority leader of the
Senate.
(b) Qualifications.--Members appointed under subsection (a) shall
possess knowledge or expertise related to human rights, civil rights,
immigration, labor, business, or other pertinent qualifications.
(c) Term of Office.--Each member shall be appointed for the life of
the Commission.
(d) Quorum.--Four members of the Commission shall constitute a
quorum, but a lesser number may hold hearings.
(e) Initial Meeting.--The initial meeting of the Commission shall
be called by the President within one hundred and twenty days after the
date of the enactment of this Act, or within thirty days after the date
on which legislation is enacted making appropriations to carry out this
Act, whichever is later.
(f) Chairperson and Vice Chairperson.--The Commission shall elect a
chairperson and vice chairperson from among its members. The term of
office of each shall be for the life of the Commission.
(g) Vacancies.--A vacancy in the Commission shall not affect its
powers and shall be filled in the same manner in which the original
appointment was made.

SEC. 6. POWERS.

(a) Hearings.--
(1) In general.--The Commission or on the authorization of
the Commission, any subcommittee or member thereof, may for the
purpose of carrying out this Act, hold hearings, sit and act at
times and places, take testimony, and receive evidence as the
Commission or any subcommittee or member considers appropriate.
(2) Location.--The Commission may hold public hearings in
any city of the United States that it finds appropriate.
(b) Subpoena Power.--
(1) In general.--The Commission may issue subpoenas
requiring the attendance and testimony of witnesses and the
production of any evidence relating to any matter under
investigation by the Commission which the Commission is
empowered to investigate by this Act.
(2) Failure to obey a subpoena.--If a person refuses to
obey a subpoena issued under paragraph (1), the Commission may
apply to a United States district court for an order requiring
that person to appear before the Commission to give testimony,
produce evidence, or both, relating to the matter under
investigation. The application may be made within the judicial
district where the hearing is conducted or where such person is
found, resides, or transacts business. Any failure to obey the
order of the court may be punished by the court as civil
contempt.
(3) Service of subpoena.--A subpoena of the Commission
shall be served in the manner provided for subpoenas issued by
a United States district court under the Federal Rules of Civil
Procedure for the United States district courts.
(4) Service of process.--All process of any court to which
application is made under paragraph (2) may be served in the
judicial district in which the person required to be served
resides or may be found.
(c) Obtaining Official Data.--The Commission may secure directly
from any department or agency of the United States, or from any State
or local government, information necessary to enable it to carry out
this Act. Upon request of any member, the head of such department or
agency shall furnish such information to the Commission.
(d) Contract Authority.--To the extent or in the amounts provided
in advance in appropriation Acts, the Commission may contract with and
compensate government and private agencies or persons for any services,
supplies, or other activities necessary to enable the Commission to
carry out its duties under this Act.

SEC. 7. STAFF.

(a) In General.--The Commission may appoint and fix the pay of such
additional staff as it considers appropriate.
(b) Applicability of Certain Civil Service Laws.--Any staff of the
Commission may be appointed without regard to the provisions of title
5, United States Code, governing appointments in the competitive
service, and may be paid without regard to the provisions of chapter 51
and subchapter III of chapter 53 of such title relating to
classification and General Schedule pay rates.
(c) Experts and Consultants.--The Commission may procure temporary
and intermittent services under section 3109(b) of title 5, United
States Code.
(d) Administrative Support Services.--Upon request of the
Commission, the Administrator of General Services shall provide to the
Commission, on a reimbursable basis, the administrative support
services necessary for the Commission to carry out its duties under
this Act.

SEC. 8. REPORT.

The Commission shall submit to Congress a written report not later
than the date which is one year after the date of the initial meeting
called pursuant to section 5(d) of this Act. The report shall contain a
detailed statement of the findings and conclusions of the Commission,
together with its recommendations for legislative actions that the
Commission considers appropriate.

SEC. 9. TERMINATION.

The Commission shall terminate 30 days after submitting the report
under section 8.

SEC. 10. DEFINITIONS.

In this Act:
(1) Commission.--The term ''Commission'' means the
Commission on the Removal of Mexican-Americans to Mexico
established under section 3.
(2) Member.--The term ''member'' means a member of the
Commission.
(3) State.--The term ''State'' means any State of the
United States, the District of Columbia, the Commonwealth of
Puerto Rico, and any other commonwealth, possession, or
territory of the United States.
[EX A]: Commission on the Removal of Mexican-Americans to Mexico This bill establishes the Commission on the Removal of Mexican-Americans to Mexico, which shall: (1) review the facts and circumstances surrounding the 1929-1941 removal of certain U.S. citizens and permanent legal residents to Mexico and the impact of such actions on such individuals, their families, and the Mexican-American community; (2) review federal, state, and local government directives that required such removal and any other related information; and (3) report its findings, conclusions, and any recommendations for legislative actions.

[EX Q]: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Drug Competition Act of 2002''.

SEC. 2. FINDINGS.

Congress finds that--
(1) prescription drug prices are increasing at an alarming
rate and are a major worry of many senior citizens and American
families;
(2) there is a potential for companies with patent rights
regarding brand name drugs and companies which could
manufacture generic versions of such drugs to enter into
financial deals that could tend to restrain trade and greatly
reduce competition and increase prescription drug expenditures
for American citizens; and
(3) enhancing competition among these companies can
significantly reduce prescription drug expenditures for
Americans.

SEC. 3. PURPOSES.

The purposes of this Act are--
(1) to provide timely notice to the Department of Justice
and the Federal Trade Commission regarding agreements between
companies with patent rights regarding brand name drugs and
companies which could manufacture generic versions of such
drugs; and
(2) by providing timely notice, to enhance the
effectiveness and efficiency of the enforcement of the
antitrust and competition laws of the United States.

SEC. 4. DEFINITIONS.

In this Act:
(1) ANDA.--The term ''ANDA'' means an Abbreviated New Drug
Application, as defined under section 201(aa) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 321(aa)).
(2) Assistant attorney general.--The term ''Assistant
Attorney General'' means the Assistant Attorney General in
charge of the Antitrust Division of the Department of Justice.
(3) Brand name drug.--The term ''brand name drug'' means a
drug approved under section 505(c) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 355(c)).
(4) Brand name drug company.--The term ''brand name drug
company'' means the party that received Food and Drug
Administration approval to market a brand name drug pursuant to
an NDA, where that drug is the subject of an ANDA, or a party
owning or controlling enforcement of any patent listed in the
Approved Drug Products With Therapeutic Equivalence Evaluations
of the Food and Drug Administration for that drug, under
section 505(b) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355(b)).
(5) Commission.--The term ''Commission'' means the Federal
Trade Commission.
(6) Generic drug.--The term ''generic drug'' means a
product that the Food and Drug Administration has approved
under section 505(j) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 355(j)).
(7) Generic drug applicant.--The term ''generic drug
applicant'' means a person who has filed or received approval
for an ANDA under section 505(j) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(j)).
(8) NDA.--The term ''NDA'' means a New Drug Application, as
defined under section 505(b) et seq. of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 355(b) et seq.)

SEC. 5. NOTIFICATION OF AGREEMENTS.

(a) In General.--
(1) Requirement.--A generic drug applicant that has
submitted an ANDA containing a certification under section
505(j)(2)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355(j)(2)(vii)(IV)) and a brand name drug company
that enter into an agreement described in paragraph (2), prior
to the generic drug that is the subject of the application
entering the market, shall each file the agreement as required
by subsection (b).
(2) Definition.--An agreement described in this paragraph
is an agreement regarding--
(A) the manufacture, marketing or sale of the brand
name drug that is the subject of the generic drug
applicant's ANDA;
(B) the manufacture, marketing or sale of the
generic drug that is the subject of the generic drug
applicant's ANDA; or
(C) the 180-day period referred to in section
505(j)(5)(B)(iv) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(j)(5)(B)(iv)) as it applies
to such ANDA or to any other ANDA based on the same
brand name drug.
(b) Filing.--
(1) Agreement.--The generic drug applicant and the brand
name drug company entering into an agreement described in
subsection (a)(2) shall file with the Assistant Attorney
General and the Commission the text of any such agreement,
except that the generic drug applicant and the brand-name drug
company shall not be required to file an agreement that solely
concerns--
(A) purchase orders for raw material supplies;
(B) equipment and facility contracts;
(C) employment or consulting contracts; or
(D) packaging and labeling contracts.
(2) Other agreements.--The generic drug applicant and the
brand name drug company entering into an agreement described in
subsection (a)(2) shall file with the Assistant Attorney
General and the Commission the text of any other agreements not
described in subsection (a)(2) between the generic drug
applicant and the brand name drug company which are contingent
upon, provide a contingent condition for, or are otherwise
related to an agreement which must be filed under this Act.
(3) Description.--In the event that any agreement required
to be filed by paragraph (1) or (2) has not been reduced to
text, both the generic drug applicant and the brand name drug
company shall file written descriptions of the non-textual
agreement or agreements that must be filed sufficient to reveal
all of the terms of the agreement or agreements.

SEC. 6. FILING DEADLINES.

Any filing required under section 5 shall be filed with the
Assistant Attorney General and the Commission not later than 10
business days after the date the agreements are executed.

SEC. 7. DISCLOSURE EXEMPTION.

Any information or documentary material filed with the Assistant
Attorney General or the Commission pursuant to this Act shall be exempt
from disclosure under section 552 of title 5, and no such information
or documentary material may be made public, except as may be relevant
to any administrative or judicial action or proceeding. Nothing in this
section is intended to prevent disclosure to either body of Congress or
to any duly authorized committee or subcommittee of the Congress.

SEC. 8. ENFORCEMENT.

(a) Civil Penalty.--Any brand name drug company or generic drug
applicant which fails to comply with any provision of this Act shall be
liable for a civil penalty of not more than $11,000, for each day
during which such entity is in violation of this Act. Such penalty may
be recovered in a civil action brought by the United States, or brought
by the Commission in accordance with the procedures established in
section 16(a)(1) of the Federal Trade Commission Act (15 U.S.C. 56(a)).
(b) Compliance and Equitable Relief.--If any brand name drug
company or generic drug applicant fails to comply with any provision of
this Act, the United States district court may order compliance, and
may grant such other equitable relief as the court in its discretion
determines necessary or appropriate, upon application of the Assistant
Attorney General or the Commission.

SEC. 9. RULEMAKING.

The Commission, with the concurrence of the Assistant Attorney
General and by rule in accordance with section 553 of title 5 United
States Code, consistent with the purposes of this Act--
(1) may define the terms used in this Act;
(2) may exempt classes of persons or agreements from the
requirements of this Act; and
(3) may prescribe such other rules as may be necessary and
appropriate to carry out the purposes of this Act.

SEC. 10. SAVINGS CLAUSE.

Any action taken by the Assistant Attorney General or the
Commission, or any failure of the Assistant Attorney General or the
Commission to take action, under this Act shall not bar any proceeding
or any action with respect to any agreement between a brand name drug
company and a generic drug applicant at any time under any other
provision of law, nor shall any filing under this Act constitute or
create a presumption of any violation of any antitrust or competition
laws.

SEC. 11. EFFECTIVE DATE.

This Act shall--
(1) take effect 30 days after the date of enactment of this
Act; and
(2) shall apply to agreements described in section 5 that
are entered into 30 days after the date of enactment of this
Act.

Passed the Senate November 18, 2002.

Attest:

JERI THOMSON,

Secretary.
[EX A]:
Drug Competition Act of 2002 - (Sec. 5) Requires a generic drug applicant that has submitted an Abbreviated New Drug Application (ANDA) and a brand name drug company that enter into an agreement, prior to the generic drug entering the market, regarding the manufacture, marketing, or sale of the brand name or the generic drug, or regarding the 180-day semi-exclusivity period referred to in the Federal Food, Drug, and Cosmetic Act as it applies to such ANDA or any other ANDA based on the same brand name drug, to each file such agreement and any related agreements with the Assistant Attorney General and the Federal Trade Commission (FTC). Makes an exception for agreements that solely concern purchase orders for raw material supplies, equipment and facility contracts, or employment or consulting contracts. Requires such agreements to be filed not later than ten business days after the date they are executed.(Sec. 7) Exempts any such information or documentary material filed from disclosure under the Freedom of Information Act. Prohibits such information or material from being made public, except as relevant to any administrative or judicial action or proceeding.(Sec. 8) Subjects an applicant or company to a civil penalty of up to $11,000 for each day such entity fails to comply with this Act, recoverable in a civil action brought by the United States or the FTC. Authorizes a U.S. district court to order compliance and grant equitable relief.